APEXIGEN INC (APGN) Stock Price & Overview
NASDAQ:APGN • US03759B1026
The current stock price of APGN is 0.3851 USD. Today APGN is up by 8.48%. In the past month the price decreased by -6.07%. In the past year, price decreased by -92.33%.
APGN Key Statistics
- Market Cap
- 9.574M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
APGN Stock Performance
APGN Stock Chart
APGN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to APGN. When comparing the yearly performance of all stocks, APGN is a bad performer in the overall market: 96.59% of all stocks are doing better.
APGN Earnings
APGN Forecast & Estimates
6 analysts have analysed APGN and the average price target is 0.65 USD. This implies a price increase of 69.51% is expected in the next year compared to the current price of 0.3851.
APGN Groups
Sector & Classification
APGN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
APGN Ownership
APGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.1 | 413.319B | ||
| AMGN | AMGEN INC | 16.73 | 203.007B | ||
| GILD | GILEAD SCIENCES INC | 16.57 | 183.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.26 | 120.332B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 81.051B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.57 | 42.097B | ||
| INSM | INSMED INC | N/A | 31.351B | ||
| NTRA | NATERA INC | N/A | 29.344B | ||
| BIIB | BIOGEN INC | 12.1 | 27.007B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.69 | 21.856B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.914B | ||
| EXAS | EXACT SCIENCES CORP | 308.97 | 19.724B | ||
| MRNA | MODERNA INC | N/A | 19.468B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About APGN
Company Profile
Apexigen, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 20 full-time employees. The company went IPO on 2021-02-02. The firm is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. The company has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. The company also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. The company is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company’s licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.
Company Info
APEXIGEN INC
900 Industrial Road, Suite C
San Carlos CALIFORNIA US
Employees: 20
Phone: 16509316236.0
APEXIGEN INC / APGN FAQ
What does APEXIGEN INC do?
Apexigen, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 20 full-time employees. The company went IPO on 2021-02-02. The firm is focused on discovering and developing antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. The company has developed a clinical-stage candidate, namely sotigalimab (sotiga or APX005M), which is a humanized agonist antibody. The company also has various preclinical and research-stage antibodies it discovered using its APXiMAB platform. The company is focused on completing ongoing clinical and manufacturing activities for the sotiga program. The Company’s licensees are advancing five product candidates in clinical development that were enabled by discoveries from its APXiMAB platform. APX005M is under Phase II clinical development for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction cancers and melanoma, in combination with chemotherapy, radiation therapy and immunotherapy.
What is the current price of APGN stock?
The current stock price of APGN is 0.3851 USD. The price increased by 8.48% in the last trading session.
Does APGN stock pay dividends?
APGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of APGN stock?
APGN has a ChartMill Technical rating of 0 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.
Which stock exchange lists APGN stock?
APGN stock is listed on the Nasdaq exchange.
Is APEXIGEN INC (APGN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on APGN.
Can you provide the number of employees for APEXIGEN INC?
APEXIGEN INC (APGN) currently has 20 employees.